SPRO
Spero Therapeutics Inc
1.20$
-3.3%
vs. previous close
Closing price · As of: Sep 28, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 83.4% | 86.2% | 93.4% | 89.5% | 89.9% | 90.7% | 92.3% | 87.4% | 71.9% | 97.0% | 97.6% | |
| 79.3% | 74.9% | 93.4% | 26.4% | 28.0% | 55.5% | 65.8% | 87.4% | 41.9% | 47.8% | 58.4% | |
| 79.3% | 74.9% | 93.4% | 89.5% | 77.3% | 82.7% | 85.6% | 87.4% | 41.9% | 47.8% | 58.4% | |
| 0.1% | 2.2% | 3.1% | 1.0% | 9.7% | 4.0% | 1.5% | 0.9% | 27.8% | 47.5% | 36.8% | |
| – | – | -5.1% | -6.8% | -12.6% | -8.0% | -0.2% | -3.6% | 0.0% | – | – | |
| 13.2% | 10.9% | 1.2% | 2.2% | 6.7% | 1.1% | 4.4% | 4.4% | – | – | – | |
| – | – | 0.0% | – | – | – | – | – | – | – | – | |
| – | – | 0.0% | – | – | – | – | – | – | – | – | |
| 103.6% | 53.8% | 9.1% | 10.2% | 29.7% | 14.0% | 48.4% | 39.2% | 41.4% | 58.3% | 14.4% | |
| 89.5% | 50.2% | 8.7% | 9.5% | 25.1% | 9.3% | 10.9% | 17.3% | 20.4% | 44.4% | 12.9% | |
| 10.2% | – | 0.2% | 0.2% | 0.9% | 0.6% | 0.8% | 1.4% | 0.9% | 1.6% | 2.8% | |
| 25.0% | 8.3% | 3.7% | 2.8% | 3.9% | 0.8% | 0.6% | 0.5% | 0.8% | 6.6% | 1.0% | |
| – | – | 0.0% | – | 0.2% | 0.1% | – | – | – | – | – | |
| 2.7% | 73.8% | 90.9% | 89.8% | 70.3% | 86.0% | 51.6% | 60.8% | 58.6% | 41.7% | 85.6% | |
| -252.2% | -329.9% | -103.6% | -107.4% | -188.0% | -181.0% | -214.8% | -331.6% | -214.4% | -415.8% | -654.5% | |
| 92.0% | 48.0% | 2.8% | 12.4% | 17.1% | 14.6% | 18.1% | 30.1% | 29.1% | 48.9% | 85.7% |
Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.